改善德国成人2型糖尿病患者的血糖、血压和血脂控制的健康与经济影响:一项建模研究
本研究使用英国前瞻性糖尿病研究结局模型2,模拟德国2型糖尿病成人患者在5年、10年和30年内的健康结局与医疗费用。结果显示,持续改善糖化血红蛋白、收缩压和低密度脂蛋白胆固醇可带来健康获益并减少医疗支出;
要点
- 持续降低糖化血红蛋白5.5 mmol/mol(0.5%)、收缩压10 mmHg或低密度脂蛋白胆固醇0.26 mmol/l,10年内人均分别节省121、238、34欧元,获得0.01、0.02、0.015个质量调整生命年。
- 未达标者实现指南推荐(糖化血红蛋白≤53 mmol/mol[7%]、收缩压≤140 mmHg、低密度脂蛋白胆固醇≤2.6 mmol/l),10年内人均分别节省451、507、327欧元,获得0.03、0.05、0.06个质量调整生命年。
核心结论
- 德国糖尿病患者持续改善糖化血红蛋白、收缩压和低密度脂蛋白胆固醇控制可带来显著健康获益并减少医疗支出。
研究设计与样本
- 使用英国前瞻性糖尿病研究结局模型2,基于德国研究的人群特征、医疗费用和健康相关生活质量数据,对德国2型糖尿病成人患者进行5年、10年和30年的患者水平健康结局与医疗费用预测。
- 模拟场景包括:所有患者糖化血红蛋白永久降低5.5 mmol/mol(0.5%)、收缩压降低10 mmHg或低密度脂蛋白胆固醇降低0.26 mmol/l;以及未达标患者实现指南推荐(糖化血红蛋白≤53 mmol/mol[7%]、收缩压≤140 mmHg、低密度脂蛋白胆固醇≤2.6 mmol/l)。
- 使用年龄和性别特异的质量调整生命年与费用估计、2型糖尿病患病率和人口规模计算全国估计值。
主要发现
- 10年内,糖化血红蛋白永久降低5.5 mmol/mol(0.5%)、收缩压降低10 mmHg或低密度脂蛋白胆固醇降低0.26 mmol/l,人均医疗支出分别节省121欧元、238欧元和34欧元,分别获得0.01、0.02和0.015个质量调整生命年。
- 未达标患者实现糖化血红蛋白、收缩压或低密度脂蛋白胆固醇的指南推荐,可分别减少医疗支出451欧元、507欧元和327欧元,并获得0.03、0.05和0.06个额外质量调整生命年。
关键数值与推荐
- 指南推荐目标:糖化血红蛋白≤53 mmol/mol(7%)、收缩压≤140 mmHg、低密度脂蛋白胆固醇≤2.6 mmol/l。
- 模拟的永久改善幅度:糖化血红蛋白降低5.5 mmol/mol(0.5%)、收缩压降低10 mmHg、低密度脂蛋白胆固醇降低0.26 mmol/l。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to estimate the long-term health and economic consequences of improved risk factor control in German adults with type 2 diabetes. METHODS: We used the UK Prospective Diabetes Study Outcomes Model 2 to project the patient-level health outcomes and healthcare costs of people with type 2 diabetes in Germany over 5, 10 and 30 years. We parameterised the model using the best available data on population characteristics, healthcare costs and health-related quality of life from German studies. The modelled scenarios were: (1) a permanent reduction of HbA1c by 5.5 mmol/mol (0.5%), of systolic BP (SBP) by 10 mmHg, or of LDL-cholesterol by 0.26 mmol/l in all patients, and (2) achievement of guideline care recommendations for HbA1c (≤53 mmol/mol [7%]), SBP (≤140 mmHg) or LDL-cholesterol (≤2.6 mmol/l) in patients who do not meet the recommendations. We calculated nationwide estimates using age- and sex-specific quality-adjusted life year (QALY) and cost estimates, type 2 diabetes prevalence and population size. RESULTS: Over 10 years, a permanent reduction of HbA1c by 5.5 mmol/mol (0.5%), SBP by 10 mmHg or LDL-cholesterol by 0.26 mmol/l led to per-person savings in healthcare expenditures of €121, €238 and €34, and 0.01, 0.02 and 0.015 QALYs gained, respectively. Achieving guideline care recommendations for HbA1c, SBP or LDL-cholesterol could reduce healthcare expenditure by €451, €507 and €327 and gained 0.03, 0.05 and 0.06 additional QALYs in individuals who did not meet the recommendations. Nationally, achieving guideline care recommendations for HbA1c, SBP and LDL-cholesterol could reduce healthcare costs by over €1.9 billion. CONCLUSIONS/INTERPRETATION: Sustained improvements in HbA1c, SBP and LDL-cholesterol control among diabetes patients in Germany can lead to substantial health benefits and reduce healthcare expenditures.
引用
- Fan M, Stephan AJ, Emmert-Fees K, et al. Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study. Diabetologia. 2023. PMID: 37391625. doi:10.1007/s00125-023-05950-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。